Start studying Farmacos Mucoliticos. Learn vocabulary, terms, and more with flashcards, games, and other study tools. Español; |; 5 Documents; |; Views. Farmacología de los antitusígenos, mucolíticos y expectorantes Share. tos farmacos · estefania · tos farmacos. Laboratorio Elea es una empresa argentina que desde investiga, produce y distribuye medicamentos confiables para diversas especialidades médicas.
|Published (Last):||11 May 2007|
|PDF File Size:||19.82 Mb|
|ePub File Size:||4.61 Mb|
|Price:||Free* [*Free Regsitration Required]|
I Professora Titular de Pneumologia. Em termos absolutos, avaliado em 24 ou 52 semanas, o aumento foi discreto, variando de 24 a 74 mL. No entanto, Calverley et al. Por sua vez, Macie et al. Segundo Rennard et al. Resultados similares foram descritos por Welte et al.
No entanto, Hanania et al. Entretanto, esses resultados devem ser interpretados com cautela. No estudo de Ernst et al. Os ICS apresentaram efeitos positivos e negativos, dependendo do desfecho estudado, com alguns efeitos adversos. Trends in the leading causes of death in the United States, Novel concepts in the pharmacotherapy of chronic obstructive pulmonary disease.
Worldwide burden of COPD in high- and low-income countries. Burden of chronic obstructive lung disease in Latin America: Int J Tuberc Lung Dis.
Obstructive lung disease and low lung function in adults in the United States: Geographic variations in prevalence and underdiagnosis of COPD: Lung function and mortality in the United States: Aclidinium bromide provides long-acting bronchodilation in patients with COPD.
Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J. Early onset of effect of salmeterol and fluticasone propionate in farmacso obstructive pulmonary disease.
Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: Nebulized arformoterol in patients with COPD: Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: Ther Adv Respir Dis.
Short-term effects of montelukast in stable patients with moderate to severe COPD. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Combination therapy in COPD: Eur Rev Med Pharmacol Sci.
Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Roflumilast farmacoa symptomatic chronic obstructive pulmonary disease: Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.
Tiotropium in combination with placebo, salmeterol, or farmzcos for treatment of chronic obstructive pulmonary disease: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: A 4-year trial of mucoliticcos in chronic obstructive pulmonary disease. N Engl J Med. Interpretative strategies for lung function tests.
Farmacs, double blind, placebo fqrmacos study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: Decramer M, Cooper CB.
Sociedade Brasileira de Pneumologia e Tisiologia. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Tiotropium and exercise training in COPD patients: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. Cardiovascular morbidity and the use of inhaled bronchodilators. Withdrawal of inhaled corticosteroids in people with COPD in primary care: Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia.
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Outcomes for COPD pharmacological trials: Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: Inhaled corticosteroids vs placebo for preventing COPD exacerbations: Evaluation of withdrawal of maintenance tiotropium in COPD.
Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.
Vademecum de Argentina – Principio activo: AMBROXOL CLEMBUTEROL
Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance mucoliticso bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
Safety of long-acting beta-agonists in stable COPD: Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. Inhaled corticosteroids for stable chronic obstructive pulmonary disease.
Inhaled corticosteroids in chronic obstructive pulmonary disease: Inhaled corticosteroids and mortality in COPD. Inhaled corticosteroids and survival in COPD patients receiving long-term home oxygen therapy.
There was a problem providing the content you requested
Short-acting inhaled betaagonists increased the mortality from chronic obstructive pulmonary disease in observational designs. Survival with tiotropium compared to long-acting Betaagonists in Chronic Obstructive Pulmonary Disease.
Comparative safety of long-acting inhaled bronchodilators: Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease.
Mucoliyicos medications and the risk of cardiac arrhythmias. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease.
Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Severity of obstructive airway disease and risk of osteoporotic fracture.
Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: Prevalence and progression of osteoporosis in patients with COPD: Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: Curr Opin Pulm Med.
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: Eur J Clin Pharmacol. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients.
Therapeutic conversion of the combination of ipratropium framacos albuterol to tiotropium in patients with chronic obstructive pulmonary disease.
J Gen Intern Med. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: Cazzola M, Matera MG. Ana M B Menezes.
Rubin, Antonio George de M. Services on Demand Journal.
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License. SCS Quadra 1, Bl. How to cite this article.